# Four Peptides, One Table, and Three Rules Nobody Puts on the Label

> The Four Side by Side — Research Peptide Fundamentals | The Peptide Train — Four Research Peptide Fundamentals research peptides compared on mechanism, duration, best human evidence and regulatory standing — and the three rules that fall out of reading them together rather than one at a time.

**THE COMPARISON**

Complementary, redundant, or neither: what the four records look like when they are laid against each other instead of read one at a time.

## Before the table: the plain version

Four peptides sit on this site. Three of them are unapproved research chemicals and one is an approved prescription medicine. They act on four different receptors, and their effects last anywhere from under half an hour to a full week.

When compounds get bundled, three things quietly happen at once. The evidence behind the bundle can only be as strong as its weakest part. The legal standing of the bundle can only be as permissive as its most restricted part. And the risks do not average out — they add up, because every constituent brings its own list.

The table below sets out what each compound is, how long it lasts, what its best human study actually found, and where it stands legally. Read across the rows and the three rules become hard to avoid. None of this ranks the four or suggests that any of them belongs with any other.

## The four, side by side

Every figure in this table comes from the numbered sources on the [reference list](/references). Blank spaces in the evidence column are not oversights; they are the finding.

| Compound | Receptor or target | Duration of action | Best human evidence | Regulatory standing | What the pairing case rests on |
| --- | --- | --- | --- | --- | --- |
| BPC-157 | VEGFR2-linked angiogenesis; no single defined receptor [4] | Elimination half-life under 30 minutes in rats and dogs [3] | One intravenous safety pilot in two adults [1]; a 2025 review counts three human pilot studies in total [2] | Not approved anywhere; research supply only; prohibited in sport at all times | Mechanism and theme only |
| CJC-1295 | GHRH receptor on pituitary somatotrophs [8] | Estimated half-life 5.8 to 8.1 days for the DAC form [11] | Single-dose pharmacology in healthy adults [11][12] | Not approved for human use; research chemical; prohibited in sport at all times | Mechanism only |
| Ipamorelin | Ghrelin receptor, GHS-R1a, on the same pituitary cells [16] | Terminal half-life about 2 hours [16] | One phase 2 randomised trial that missed its primary endpoint [15] | Not approved for any indication; research chemical; prohibited in sport at all times | Mechanism only, and its own record says so |
| Tirzepatide | GIP receptor and GLP-1 receptor, one molecule [19] | Once-weekly dosing across phase 3 trials [21][22] | Multiple phase 3 randomised trials including a head-to-head against a single-receptor comparator [18][21][22] | FDA-approved prescription medicine [19]; not specifically prohibited in sport | Randomised head-to-head evidence [18][22] |

The rightmost column is the one this desk built the site around. Three rows say *mechanism*. One row says *evidence*.

## Complementary, redundant, or neither

The frame for this hub is why peptides get studied together — which pairings are additive, which are synergistic, and which are simply redundant. Laid against these four records, the categories sort out more sharply than the marketing does.

**Genuinely complementary, in mechanism.** CJC-1295 acts at the GHRH receptor [8]. Ipamorelin acts at the ghrelin receptor on the same pituitary cells and produces its own discrete growth-hormone pulse about forty minutes after dosing [16]. Two separate receptors converging on one output is a real pharmacological distinction, not a marketing one, and it is reinforced by the measured observation that pulsatile secretion persists rather than flattening under continuous GHRH-analogue stimulation [12].

**Redundant, in risk.** The same two compounds overlap almost completely on the downside. Both raise growth hormone and therefore IGF-1 exposure. Both carry fluid-retention concerns in their own safety records, and both carry concerns about insulin sensitivity and blood glucose. The mechanisms diverge on the way in and reconverge on the way out. Whatever a pairing adds in hoped-for benefit, it demonstrably doubles up on documented concern.

**Neither.** BPC-157 with anything else is a thematic pairing rather than a pharmacological one. *Repair* is a category, not a target, and a category can be extended over any compound without contradiction. Add the fact that its elimination half-life in animals is under 30 minutes [3] while a DAC-form partner persists for the better part of a week [11], and the two are not really acting in concert at all.

**Synergy is the word to watch.** Nothing on this page measured synergy. Synergy is a specific, testable claim that a combination produces more than the sum of its parts, and testing it requires giving the combination and measuring the outcome against each single agent. That study does not exist for any pairing here. The only compound on this site with a genuine head-to-head result is tirzepatide, and its comparison was against another drug, not against its own constituents [18][22].

## The clocks do not line up

One practical objection to bundling these particular compounds gets almost no attention, and it is not a subtle one.

BPC-157's elimination half-life in rats and dogs is under 30 minutes [3]. Ipamorelin's terminal half-life in healthy human volunteers is about two hours, with its growth-hormone response arriving as a single pulse peaking around forty minutes [16]. The DAC form of CJC-1295 has an estimated half-life of 5.8 to 8.1 days, keeping IGF-1 above baseline for as long as 28 days after repeated administration [11]. Tirzepatide is dosed once weekly across its phase 3 programme [21][22].

That is a spread of roughly three orders of magnitude between the shortest and the longest. Compounds whose exposure windows differ that dramatically are not really present in the body *together* in any meaningful sense — they are separate exposures on separate timelines that happen to have been purchased in the same order.

And this is exactly the kind of question a combination study would answer: whether a short pulse layered onto a multi-day background does anything different from either alone, and whether the timing between them matters. Nobody has run it. The literature on these four contains no pharmacokinetic characterisation of any pairing.

## The only tested combination here

Tirzepatide is on this site as a control case rather than as a recommendation.

It is a combination in the functional sense — two incretin receptors engaged by one 39-amino-acid molecule [19] — and it is the only one whose two-mechanism premise was put through a test that could have failed. It was compared against a single-receptor agent over 72 weeks in 751 adults with obesity, producing a mean weight change of -20.2% against -13.7% [18], and over 40 weeks in 1,879 adults with type 2 diabetes, producing larger reductions in glycated haemoglobin at every dose than semaglutide 1 mg [22].

That sequence — argue the mechanism, build it, then measure it against the alternative — is what separates evidence from rationale. It is also expensive, slow and frequently unflattering, which is why bundles assembled from existing vials skip it.

The comparison is not that tirzepatide is better than the other three. It treats different problems, in different people, under a different legal regime. The comparison is that its combination claim was tested and theirs were not.

## Three rules that fall out of reading these four together

**1. The weakest-evidenced constituent sets the evidence ceiling.** A combination cannot be better supported than its least-supported part, because any claim made for the whole depends on every component behaving as assumed. A pairing containing a compound whose human record is three pilot studies [2] inherits that record, however well characterised its partner is.

**2. The most restricted constituent sets the regulatory floor — and the most permissive one cannot lift it.** This is the mirror image of the first rule and it is the one most often got backwards. Tirzepatide's approval [19] is a fact about tirzepatide. It does not travel to whatever is placed beside it. A bundle containing one approved medicine and one unapproved research chemical is not partly approved; it is an unapproved combination that contains an approved ingredient. The same reasoning applies to sport: three of these four are prohibited at all times, and pairing a banned compound with a permitted one does not produce a permitted product.

**3. Risk is a union, not an average.** Each of these four brings its own documented cautions, and combining them combines the lists rather than diluting them. Where the cautions overlap the concern concentrates instead of cancelling — two growth-hormone-axis compounds together mean two sources of IGF-1 elevation, two fluid-retention concerns and two glycaemic concerns. And a combination can generate a risk that belongs to neither component alone: the clearest documented example on this whole site is hypoglycaemia, which is low with tirzepatide by itself because its insulin effect is glucose-dependent, and which rises when it is combined with insulin or a sulfonylurea [19].

## What this comparison cannot say

Three limits, stated plainly, because a table this tidy invites over-reading.

**It cannot say that any pairing does not work.** No combination trial exists for three of the four compounds here. Absence of evidence is not evidence of absence, and this desk does not claim otherwise. What can be said is narrower and firmer: any confident claim about what a combination *does* is currently unsupported, in either direction.

**It is not a ranking.** The four compounds are studied for different things in different populations. Tirzepatide's large randomised programme does not make it the right subject for a tendon-repair question, and BPC-157's animal tendon results do not compete with a glycaemic endpoint. Depth of evidence and relevance of evidence are different axes.

**It cannot substitute for the labelling or for a clinician.** Nothing here is advice, and no dose, schedule or pairing is suggested to anyone. This is a reading of published sources, and the sources are all listed on the [reference page](/references) so that any figure quoted here can be checked at source.

---

The Peptide Train follows four habitually bundled peptides back through their own published records and reports the exact point where the reporting has to stop — it sells nothing, prescribes nothing, and endorses no pairing to anyone.